Imagine you're with two potential customers. You paste on your best smile, offer your help and information, ask a multitude of questions to gain rapport and then close the sale. But somehow, the customers escape without giving you any kind of commitment. What went wrong?
Imagine you're with two potential customers. You paste on your best smile, offer your help and information, ask a multitude of questions to gain rapport and then close the sale. But somehow, the customers escape without giving you any kind of commitment. What went wrong?
The answer may be that you treated them like sales, not people. You failed to demonstrate that you care. You were pushy. There's a fine line between scaring customers away and not being aggressive enough, according to the "Sales Success Profile," a sales aptitude test. You need to be a "balanced" closer.
Balanced closers are not exceptionally polite, but have approachable good natures. On the test, their warm and friendly traits score almost exactly between their closing skills and how polite or courteous they are.
Extremely aggressive closers, on the other hand, score high on closing skills but very low in both politeness and friendliness. They care only about closing sales and will do almost anything to reach that goal. They may not do well in careers that require long-term, repeat visits.
At the other end of the spectrum, some salespeople are poor closers, extremely polite or courteous and very friendly. They are reluctant to ask for sales and won't attempt to close a second time if they fail on the first attempt. But they can become good salespeople if they learn closing techniques.
The easiest way to avoid being pushy is to care about your customers. Listen, discover their wants and needs in a non-threatening manner and show them how your product can answer their needs. Don't, however, lose focus of why you're there.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.